RecruitingPHASE1, PHASE2NCT07558733

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Studying Hereditary breast cancer

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Faeth Therapeutics
Intervention
Serabelisib(drug)
Enrollment
32 enrolled
Eligibility
18 years · All sexes
Timeline
20262033

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07558733 on ClinicalTrials.gov

Other trials for Hereditary breast cancer

Additional recruiting or active studies for the same condition.

See all trials for Hereditary breast cancer

← Back to all trials